Taking Big Pharma’s R&D Argument Literally: Cut Prices, Or Increase Spending?
Executive Summary
Former Obama Administration official offers sophisticated and complicated approach to value-based pricing, tied back to drug development costs. The complexity alone makes the idea a non-starter for the current Administration, but it also begs the question of whether it would be more likely to cut costs – or just increase R&D spending?
You may also be interested in...
The Latest Furor Over Trump’s Drug Pricing Plan
Did the head of the Office and Management & Budget really endorse Part D rebates? Like so much about the Trump Administration’s response to drug pricing, there is probably a lot less to the story than it sounds.
Putting The 'Big' Back In PhRMA: New Membership Criteria Pares Ranks
PhRMA eliminates 42% of members in conjunction with new membership eligibility criteria stipulating minimum R&D investment levels.
“Frank” Talk On Drug Pricing: HHS Official Sees Value-Based Pricing As Area Of Common Interest
The most likely next step in executive branch action on drug pricing will be testing approaches to value-based pricing in categories where pharmaceutical companies are willing participants. That appears to be the message from an HHS official speaking at a DC policy event.